Lesperance M - Search Results

1

Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer.

Hout DR, Schweitzer BL, Lawrence K, Morris SW, Tucker T, Mazzola R, Skelton R, McMahon F, Handshoe J, Lesperance M, Karsan A, Saltman DL. Hout DR, et al. Among authors: lesperance m. Cancers (Basel). 2017 Aug 1;9(8):99. doi: 10.3390/cancers9080099. Cancers (Basel). 2017. PMID: 28763012 Free PMC article.

2

Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab.

Freeman AT, Lesperance M, Wai ES, Croteau NS, Fiorino L, Geller G, Brooks EG, Poonja Z, Fenton D, Irons S, Ksienski D. Freeman AT, et al. Among authors: lesperance m. Curr Oncol. 2020 Apr;27(2):76-82. doi: 10.3747/co.27.5495. Epub 2020 May 1. Curr Oncol. 2020. PMID: 32489249 Free PMC article.

3

Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.

Ksienski D, Wai ES, Croteau N, Fiorino L, Brooks E, Poonja Z, Fenton D, Geller G, Glick D, Lesperance M. Ksienski D, et al. Among authors: lesperance m. Clin Lung Cancer. 2019 Jan;20(1):e97-e106. doi: 10.1016/j.cllc.2018.09.005. Epub 2018 Sep 22. Clin Lung Cancer. 2019. PMID: 30337270

4

Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab.

Ksienski D, Wai ES, Alex D, Croteau NS, Freeman AT, Chan A, Patterson T, Clarkson M, Fiorino L, Poonja Z, Fenton D, Irons S, Lesperance M. Ksienski D, et al. Among authors: lesperance m. Transl Lung Cancer Res. 2021 Jan;10(1):355-367. doi: 10.21037/tlcr-20-541. Transl Lung Cancer Res. 2021. PMID: 33569318 Free PMC article.

5

First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic.

Lakkunarajah S, Truong PT, Bone JN, Hughesman C, Yip S, Alex D, Hart J, Pollock P, Egli S, Clarkson M, Lesperance M, Ksienski D. Lakkunarajah S, et al. Among authors: lesperance m. Transl Lung Cancer Res. 2023 Jul 31;12(7):1454-1465. doi: 10.21037/tlcr-23-81. Epub 2023 Jul 21. Transl Lung Cancer Res. 2023. PMID: 37577326 Free PMC article.

6

Durvalumab Following Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Differences in Survival Based on Age and Post-Progression Systemic Therapy.

Ksienski D, Truong PT, Bone JN, Egli S, Clarkson M, Patterson T, Lesperance M, Lakkunarajah S. Ksienski D, et al. Among authors: lesperance m. Target Oncol. 2024 Nov 4. doi: 10.1007/s11523-024-01111-7. Online ahead of print. Target Oncol. 2024. PMID: 39489887

7

Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis.

Ludbrook JJ, Truong PT, MacNeil MV, Lesperance M, Webber A, Joe H, Martins H, Lim J. Ludbrook JJ, et al. Among authors: lesperance m. Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1321-30. doi: 10.1016/s0360-3016(02)04576-5. Int J Radiat Oncol Biol Phys. 2003. PMID: 12654444 Review.

8

Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.

Ksienski D, Wai ES, Croteau N, Freeman AT, Chan A, Fiorino L, Brooks EG, Poonja Z, Fenton D, Geller G, Irons S, Lesperance M. Ksienski D, et al. Among authors: lesperance m. Lung Cancer. 2019 Jul;133:110-116. doi: 10.1016/j.lungcan.2019.05.005. Epub 2019 May 18. Lung Cancer. 2019. PMID: 31200816

9

Safety and efficacy of pembrolizumab for advanced nonsmall cell lung cancer: before and during the COVID-19 pandemic.

Ksienski D, Gupta S, Truong PT, Bone J, Chan A, Alex D, Hart J, Pollock P, Patterson T, Clarkson M, Dissanayake D, Sonke E, Lesperance M. Ksienski D, et al. Among authors: lesperance m. J Cancer Res Clin Oncol. 2023 Jul;149(7):2951-2961. doi: 10.1007/s00432-022-04181-0. Epub 2022 Jul 14. J Cancer Res Clin Oncol. 2023. PMID: 35834010 Free PMC article.

10

Examining time intervals between diagnosis and treatment in the management of patients with limited stage small cell lung cancer.

Berthelet E, Truong PT, Lesperance M, Lim JT, Wai ES, MacNeil MV, Liu M, Joe H, Olivotto IA. Berthelet E, et al. Among authors: lesperance m. Am J Clin Oncol. 2006 Feb;29(1):21-6. doi: 10.1097/01.coc.0000195092.25516.19. Am J Clin Oncol. 2006. PMID: 16462498

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

174 results

Search Page

Filters